- Home
- CSGS vs XNCR Comparison
CSGS vs XNCR Comparison
Compare CSGS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSGS | XNCR |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 881.9M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CSGS | XNCR |
|---|---|---|
| Price | $80.05 | $12.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $72.43 | $22.33 |
| AVG Volume (30 Days) | 375.8K | ★ 833.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $996,810,000.00 | $125,576,000.00 |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $3.02 | $11.88 |
| P/E Ratio | $40.43 | ★ N/A |
| Revenue Growth | ★ 13.91 | 13.65 |
| 52 Week Low | $54.65 | $6.92 |
| 52 Week High | $80.67 | $18.69 |
Technical Indicators
Market Signals| Indicator | CSGS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 57.40 |
| Support Level | $79.41 | $12.29 |
| Resistance Level | $80.22 | $12.87 |
| Average True Range (ATR) | 0.31 | 0.76 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 56.12 | 99.20 |
Price Performance
Historical ComparisonAbout CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, it generates revenue from the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.